Cargando…
Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments
BACKGROUND: Mpox virus (MPXV) is a zoonotic orthopoxvirus and caused an outbreak in 2022. Although tecovirimat and brincidofovir are approved as anti-smallpox drugs, their effects in mpox patients have not been well documented. In this study, by a drug repurposing approach, we identified potential d...
Autores principales: | Akazawa, Daisuke, Ohashi, Hirofumi, Hishiki, Takayuki, Morita, Takeshi, Iwanami, Shoya, Kim, Kwang Su, Jeong, Yong Dam, Park, Eun-Sil, Kataoka, Michiyo, Shionoya, Kaho, Mifune, Junki, Tsuchimoto, Kana, Ojima, Shinjiro, Azam, Aa Haeruman, Nakajima, Shogo, Park, Hyeongki, Yoshikawa, Tomoki, Shimojima, Masayuki, Kiga, Kotaro, Iwami, Shingo, Maeda, Ken, Suzuki, Tadaki, Ebihara, Hideki, Takahashi, Yoshimasa, Watashi, Koichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469127/ https://www.ncbi.nlm.nih.gov/pubmed/36892247 http://dx.doi.org/10.1093/infdis/jiad058 |
Ejemplares similares
-
Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents
por: Hishiki, Takayuki, et al.
Publicado: (2023) -
Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro
por: Shionoya, Kaho, et al.
Publicado: (2021) -
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
por: Ohashi, Hirofumi, et al.
Publicado: (2022) -
Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
por: Tatematsu, Daiki, et al.
Publicado: (2023) -
Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma
por: Iwanami, Shoya, et al.
Publicado: (2020)